Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 2a study of luspatercept in beta-thalassemia
2022-502499-22-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Oct 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, open-label trial of luspatercept in beta thalassemia and hemoglobin E beta thalassemia (HbE/β-thal) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Recommended dose based on dose-limiting toxicities and safety and Pharmacokinetics of luspatercept. Planned start Oct 2019; status: authorised.
02
Drugs
luspatercept
03
Conditions
beta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on 2022-502499-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502499-22-00.